GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (FRA:BD5) » Definitions » Net-Net Working Capital

BioDelivery Sciences International (FRA:BD5) Net-Net Working Capital : €0.28 (As of Dec. 2021)


View and export this data going back to 2004. Start your Free Trial

What is BioDelivery Sciences International Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

BioDelivery Sciences International's Net-Net Working Capital for the quarter that ended in Dec. 2021 was €0.28.

The industry rank for BioDelivery Sciences International's Net-Net Working Capital or its related term are showing as below:

FRA:BD5's Price-to-Net-Net-Working-Capital is not ranked
in the Drug Manufacturers industry.
Industry Median: 7.555 vs FRA:BD5: 17.41

BioDelivery Sciences International Net-Net Working Capital Historical Data

The historical data trend for BioDelivery Sciences International's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Net-Net Working Capital Chart

BioDelivery Sciences International Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.73 -0.27 -0.14 0.20 0.28

BioDelivery Sciences International Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.23 0.27 0.19 0.28

Competitive Comparison of BioDelivery Sciences International's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioDelivery Sciences International's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where BioDelivery Sciences International's Price-to-Net-Net-Working-Capital falls into.



BioDelivery Sciences International Net-Net Working Capital Calculation

BioDelivery Sciences International's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2021 is calculated as

Net-Net Working Capital(A: Dec. 2021 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(101.163+0.75 * 50.327+0.5 * 20.984-121.045
-0-0)/101.536
=0.28

BioDelivery Sciences International's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2021 is calculated as

Net-Net Working Capital(Q: Dec. 2021 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(101.163+0.75 * 50.327+0.5 * 20.984-121.045
-0-0)/101.536
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


BioDelivery Sciences International  (FRA:BD5) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


BioDelivery Sciences International Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (FRA:BD5) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

BioDelivery Sciences International (FRA:BD5) Headlines

No Headlines